Ready when it matters most

Nuclear & Radiological Emergency Antidotes

Golden Hour Pharma specialises in manufacturing and supplying essential nuclear and radiological emergency medicines and antidotes — mandatory for every country to stockpile as part of national preparedness for radiation emergencies.

These medicines are recommended for national stockpiles by the USFDA, the U.S. Centers for Disease Control and Prevention (CDC), and the World Health Organization (WHO) to protect populations during nuclear incidents, radiation exposure, or contamination. They are manufactured to WHO-GMP standards.

WHO-GMP Certified

Discuss Your Preparedness Requirements

Nuclear Emergency Antidotes

Coming Soon

Video Placeholder

Nuclear Emergency Antidotes

Coming Soon

Video Placeholder

Complete Antidote Portfolio

Nine FDA-approved and WHO-recommended medicines covering all categories of nuclear and radiological emergency response.

01 Potassium Iodide (KI)

Indication

Radioactive Iodine (I-131) Exposure / Thyroid Blocking Agent

Timing

Before or immediately after exposure

Mechanism

Thyroid saturation to block I-131 uptake; stable iodine supplementation for thyroid protection

Prevents radiation-induced thyroid cancer

Saturates the thyroid gland with stable iodine

Core component of all national emergency stockpiles

Available in tablet form for mass-distribution

WHO and IAEA recognised for national emergency use

02 Prussian Blue (Ferric Hexacyanoferrate)

FDA Approved (Radiogardase)

Indication

Cesium-137 & Thallium Contamination

Timing

After confirmed internal contamination

Mechanism

Binds radioactive particles in the gut, enhancing fecal elimination

FDA approved for radioactive cesium-137 and thallium since 2003

Reduces biological half-life of cesium in the body

Oral administration — suitable for mass casualty scenarios

Recommended by CDC and WHO — mandatory for every country to stockpile

Taken immediately before or after exposure

Essential for civil defense and disaster response stockpiles

03 Calcium-DTPA (Ca-DTPA)

FDA Approved (2004)

Indication

Plutonium, Americium, Curium Contamination

Timing

Best administered within the first 24 hours of exposure

Mechanism

Chelates radioactive heavy metals, enhances urinary excretion

FDA approved for decorporation of plutonium, americium, curium since 2004

Most effective when administered promptly after exposure

Available as intravenous or nebulised inhalation

Accelerates elimination of transuranic radionuclides

Part of standard government nuclear emergency protocols

04 Zinc-DTPA (Zn-DTPA)

FDA Approved

Indication

Plutonium, Americium, Curium — Long-Term Treatment

Timing

After the first 24 hours; suitable for long-term treatment

Mechanism

Chelation therapy for transuranic radionuclide decorporation

FDA approved for the same indications as Ca-DTPA

Preferred for long-term administration due to lower mineral depletion risk

Reduces radiation dose to vital organs over extended treatment

Can be combined with Ca-DTPA in initial treatment protocols

Recommended for chronic low-level exposure management

05 Filgrastim (G-CSF)

FDA Approved for ARS (2015)

Indication

Acute Radiation Syndrome (ARS) — Bone Marrow Suppression

Timing

Within 24 hours following significant radiation exposure

Mechanism

Stimulates white blood cell production to combat radiation-induced neutropenia

FDA approved for Acute Radiation Syndrome management

Stimulates granulocyte colony-stimulating factor production

Significantly reduces infection risk in radiation-exposed patients

Improves survival outcomes in hematopoietic radiation injury

Standard of care in all national ARS management protocols

06 Pegfilgrastim

FDA Approved for ARS

Indication

Acute Radiation Syndrome — Long-Acting G-CSF

Timing

Single-dose administration post-exposure

Mechanism

Long-acting granulocyte stimulating factor for sustained neutrophil recovery

Long-acting formulation of G-CSF — single dose advantage

FDA approved for radiation-induced neutropenia

Reduces the burden of repeated daily injections in mass casualty settings

Particularly suited for large-scale disaster response scenarios

Maintains efficacy over extended period with one administration

07 Sargramostim (GM-CSF)

FDA Approved

Indication

Hematopoietic Radiation Injury

Timing

Following acute radiation exposure affecting bone marrow

Mechanism

Stimulates granulocyte and macrophage production; supports bone marrow recovery

FDA approved for hematopoietic radiation injury

Stimulates both granulocyte and macrophage production

Supports broader bone marrow recovery versus G-CSF alone

Used in multi-agent ARS treatment protocols

Improves overall immune system reconstitution post-exposure

08 Sodium Bicarbonate

Supportive Medical Management Protocol

Indication

Uranium Exposure — Renal Protection

Timing

As soon as possible following uranium exposure

Mechanism

Alkalinises urine to protect kidneys and enhance uranium excretion

Protects kidneys from uranium-induced nephrotoxicity

Alkalinises urine to prevent uranium reabsorption

Widely available and cost-effective intervention

First-line supportive care in uranium contamination scenarios

Included in government uranium exposure management guidelines

09 Strontium Binding Agents

Supportive Decorporation Therapy

Indication

Strontium-90 Contamination

Timing

As early as possible post-ingestion exposure

Mechanism

Reduces gastrointestinal absorption of radioactive strontium

Potassium Phosphate and Aluminum Hydroxide used as binding agents

Reduces GI absorption of strontium-90

Part of multi-agent decorporation therapy protocols

Included in WHO recommendations for strontium contamination

Complementary to other decorporation treatments

Mandatory National Stockpile Medicines

The following medicines are recommended by USFDA, CDC, and WHO as mandatory components of every national emergency preparedness stockpile:

Potassium Iodide (KI)Thyroid Blocking Agent

Prussian Blue (Ferric Hexacyanoferrate)Decorporation Agent

Calcium-DTPA & Zinc-DTPAChelation Therapy

Filgrastim / Pegfilgrastim (G-CSF)Hematopoietic Support

Sargramostim (GM-CSF)Hematopoietic Support

Sodium Bicarbonate (for uranium exposure)Renal Protection

Strontium Binding AgentsDecorporation Agent

Acute Radiation Syndrome (ARS) Protocol

Acute Radiation Syndrome is a serious, life-threatening condition caused by significant radiation exposure. The following multi-agent treatment approach is the standard of care in international ARS management protocols:

Hematopoietic growth factors (Filgrastim, Pegfilgrastim, Sargramostim)

Decorporation agents (DTPA, Prussian Blue)

Thyroid blocking (Potassium Iodide)

Ferric Hexacyanoferrate (Prussian Blue) — Mandatory to stockpile for every country for Cesium and Thallium exposure

Blood products and ICU supportive care

Broad-spectrum antibiotics for infection prophylaxis

Who We Serve

Emergency Preparedness Applications

Our nuclear emergency antidotes support governments, civil defense agencies, and healthcare institutions across multiple emergency preparedness scenarios.

Nuclear Power Plant Incidents

Rapid antidote deployment is critical following nuclear facility accidents. Golden Hour Pharma maintains dedicated sourcing channels to provide thyroid blocking agents, DTPA, and supportive ARS medicines for rapid national response.

Radiological Dispersal Devices (Dirty Bombs)

Civil defense preparedness requires pre-positioned stockpiles of Prussian Blue, DTPA agents, and thyroid protectants to address contamination from radiological weapons in civilian populations.

National Strategic Medical Stockpiles

Government health ministries and civil defense agencies worldwide are required to maintain strategic stockpiles of nuclear emergency antidotes. We provide compliant, long-shelf-life formulations for institutional procurement.

Disaster Response & Public Health Emergencies

International health organisations and disaster management bodies rely on pre-positioned pharmaceutical supply for large-scale radiological emergencies. Our 365 days emergency readiness capability supports rapid deployment.

Why Golden Hour Pharma

The Specialist Partner for Nuclear Emergency Preparedness

Golden Hour Pharma is one of the few specialised pharmaceutical companies with deep expertise in nuclear and radiological emergency antidotes. We manufacture to WHO-GMP standards, providing governments and healthcare institutions with reliable, compliant, and affordable emergency countermeasures.

WHO-GMP Certified manufacturing facilities

Full regulatory documentation and traceability records

Long shelf-life formulations suitable for strategic stockpiling

365 days emergency readiness capability — always prepared

Competitive, transparent pricing for institutional and government buyers

Experience supplying government health authorities across 30+ countries

Discuss Your Preparedness Requirements

Antidote Products

FDA approved & WHO recommended

30+

Countries Served

Government & institutional supply

365 Days

Emergency Readiness

365 days a year readiness

WHO-GMP

Certified Standards

Highest global benchmarks

Ready to Build Your National Stockpile?

Contact our team to discuss your specific preparedness requirements, regulatory documentation needs, and delivery timelines. We serve government health authorities, civil defense agencies, hospitals, and international health organisations.

Submit an Inquiry About Golden Hour Pharma